Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed as a multicenter, double-blinded, randomized, placebo controlled study
to assess the safety and efficacy of JBM-TC4 for the prevention and treatment of acute
radiation-induced dermatitis in breast cancer patients receiving radiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Joben Bio-Medical Co., Ltd.
Collaborators:
Efficient Pharma Management Corp. Kaohsiung Medical University Chung-Ho Memorial Hospital Taipei Veterans General Hospital, Taiwan